Skip Navigation LinksHome > January 2008 - Volume 14 - Issue 1 > Discriminating IBD from IBS: Comparison of the test performa...
Inflammatory Bowel Diseases:
doi: 10.1002/ibd.20275
Original Clinical Articles

Discriminating IBD from IBS: Comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies

Schoepfer, Alain M. MD1,*; Trummler, Michael MD2; Seeholzer, Petra3; Seibold‐Schmid, Beatrice MSc4; Seibold, Frank MD1

Collapse Box

Abstract

Background:: Symptoms of inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) can overlap. We aimed to determine the accuracy of fecal markers, C‐reactive protein (CRP), blood leukocytes, and antibody panels for discriminating IBD from IBS and to define a “best test.”

Methods:: We prospectively included 64 patients with IBD (36 Crohn's disease [CD], 28 ulcerative colitis [UC]), 30 with IBS, and 42 healthy controls. Besides CRP and blood leukocytes, blinded fecal samples were measured for calprotectin (PhiCal Test, enzyme‐linked immunosorbent assay [ELISA]), lactoferrin (IBD‐SCAN, ELISA), Hexagon‐OBTI (immunochromatographic test for detection of human hemoglobin), and LEUKO‐TEST (lactoferrin latex‐agglutination test). Blinded serum samples were measured for the antibodies ASCA (ELISA) and pANCA (immunofluorescence).

Results:: Overall accuracy of tests for discriminating IBD from IBS: IBD‐SCAN 90%, PhiCal Test 89%, LEUKO‐TEST 78%, Hexagon‐OBTI 74%, CRP 73%, blood leukocytes 63%, CD antibodies (ASCA+/pANCA− or ASCA+/pANCA+) 55%, UC antibodies (pANCA+/ASCA−) 49%. ASCA and pANCA had an accuracy of 78% for detecting CD and 75% for detecting UC, respectively. The overall accuracy of IBD‐SCAN and PhiCal Test combined with ASCA/pANCA for discriminating IBD from IBS was 92% and 91%, respectively.

Conclusions:: The PhiCal Test and IBD‐SCAN are highly accurate for discriminating IBD from IBS. There is only marginal additional diagnostic accuracy when the PhiCal Test and IBD‐SCAN are combined with ASCA and pANCA. ASCA and pANCA have a high specificity for IBD.

© Crohn's & Colitis Foundation of America, Inc.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.